Biotest
Athanasios Dakas has an extensive work experience in the field of internal audit. Athanasios is currently the Head of Internal Audit at Biotest AG, a global company that supplies plasma protein products and biotherapeutic drugs. In this role, they are responsible for the Corporate Internal Audit Function of the Biotest Group. Prior to this, they worked as the Head of Division and Internal Audit Director at TASCO Revision und Beratung, where they provided internal audit consultancy for mandates in various industries. Athanasios was also a Senior Head of Department and Senior Audit Manager at Tengelmann Audit GmbH, where they handled the Corporate Audit Function of the Tengelmann Group and provided internal audit consultancy for external mandates in various industries. Throughout their career, Athanasios Dakas has gained expertise in auditing and consulting services in sectors such as retail, wholesale, industry, energy, e-commerce, pharmaceuticals, and non-profit organizations.
Athanasios Dakas holds a Bachelor of Arts (B.A.) degree in Business Administration from the University of Cooperative Education in Frankfurt am Main, which they completed from 2005 to 2008. Athanasios also obtained the certification of Certified Internal Auditor (CIA) from the Institute of Internal Auditors (IIA) in Lake Mary, Florida, USA, which they completed in 2013. Additionally, they hold the title of Wholesale and Foreign Trade Merchant from the Chamber of Commerce and Industry in Frankfurt am Main. Furthermore, Athanasios Dakas has the certification of "Prüfer für Interne Revisionssysteme DIIR" which stands for Certified Auditor for Internal Audit Systems from the German Institute of Internal Auditors (DIIR), based in Frankfurt am Main.
This person is not in any teams
This person is not in any offices
Biotest
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.